Floatz Rating
BB64/100
Confidence
Indicative
Sponsor
Therapeutic Advances in Childhood Leukemia Consortium
Modality
Small molecule
Development Phase
Phase 3
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
52Moderate confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT05476770CT.gov Tagraxofusp in Pediatric Patients With Relapsed or Refractory CD123 Expressing Hematologic Malignancies | — | Recruiting | — | — | — |
NCT00557193CT.gov Combination Chemotherapy With or Without Lestaurtinib in Treating Younger Patients With Newly Diagnosed Acute Lymphoblastic Leukemia | — | Completed | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
89High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Acute Undifferentiated Leukemia
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Hydrocortisone (this asset) | Therapeutic Advances in Childhood Leukemia Consortium | P3 | BB · 64 |
| Fludarabine | Fred Hutchinson Cancer Center | P2 | BB |
| Vincristine Sulfate | M.D. Anderson Cancer Center | P3 | BB |
| Dexasone | Therapeutic Advances in Childhood Leukemia Consortium | P3 | BB |
| Cytarabine | Fred Hutchinson Cancer Center | P3 | BB |
| Cyclophosphamide | Masonic Cancer Center, University of Minnesota | P3 | BB |
| Nivestim | Fred Hutchinson Cancer Center | P3 | BB |
| Daunomycin | Syndax Pharmaceuticals | P3 | BB |
| Methotrexate | Therapeutic Advances in Childhood Leukemia Consortium | P3 | BB |
+42 more in the Acute Undifferentiated Leukemia cohort
Other indications for Hydrocortisone
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Congenital Adrenal Hyperplasia | — | P4 | A · 81 |
| Childhood Acute Lymphoblastic Leukemia | — | P3 | BB · 68 |
| Adrenocortical Insufficiency | — | P3 | BB · 68 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Hydrocortisone in Acute Undifferentiated Leukemia. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/hydrocortisone-acute-undifferentiated-leukemia
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →